Financiere des Professionnels Fonds d investissement inc. decreased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,978 shares of the medical instruments supplier's stock after selling 2,078 shares during the period. Becton, Dickinson and Company comprises about 1.3% of Financiere des Professionnels Fonds d investissement inc.'s investment portfolio, making the stock its 15th biggest position. Financiere des Professionnels Fonds d investissement inc.'s holdings in Becton, Dickinson and Company were worth $20,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at $27,000. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $29,000. REAP Financial Group LLC lifted its position in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Picton Mahoney Asset Management lifted its position in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 54 shares during the period. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at about $34,000. Institutional investors own 86.97% of the company's stock.
Insider Buying and Selling
In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
Becton, Dickinson and Company Trading Down 1.8%
Shares of NYSE BDX traded down $3.24 during mid-day trading on Monday, reaching $172.92. The company had a trading volume of 2,499,589 shares, compared to its average volume of 2,065,561. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The business's 50-day moving average is $173.94 and its 200-day moving average is $207.57. The stock has a market cap of $49.56 billion, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the firm earned $3.17 earnings per share. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.
Analysts Set New Price Targets
A number of analysts have recently commented on BDX shares. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research note on Friday, May 2nd. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a report on Thursday, May 1st. Morgan Stanley decreased their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Finally, Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $219.22.
Get Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
